High Prevalence of Growth Hormone Deficiency in Severe Fibromyalgia Syndromes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CONTEXT: Fibromyalgia (FM) is characterized by widespread pain and fatigue and is considered a syndrome with different pathogenic mechanisms. Controversial data on GH axis disturbances have been published. Some preliminary trials have shown promising effects of GH therapy on tender points and quality of life in FM. AIM: The aim was to study the patterns of GH secretion/sensitivity in a cohort of severe FM patients. SETTING: The study was conducted in five tertiary hospitals. METHODS: A total of 493 FM women (1990 American College of Rheumatology criteria) recruited from five centers, having more than 16 tender points, Fibromyalgia Impact Questionnaire scores above 75, more than 1 yr of stable medication (serotonin reuptake inhibitors, amitriptyline, and opioids), and body mass index below 35 kg/m(2) underwent baseline IGF-I/GH determinations; an insulin tolerance test (ITT) and a modified IGF-I generation test were performed in those cases showing IGF-I of 150 microg/liter or less. RESULTS: A total of 169 of the 493 patients (34.2%) showed IGF-I of 150 microg/liter or less. Mean peak GH during ITT was 13.3 +/- 9.9 ng/ml in 127 patients in which the test was performed. In 22 of 127 (17.3%), ITT peak GH was 5 microg/ml or less, and in eight of them (6.3%), the peak GH was 3 ng/ml or less. Mean baseline GH (n = 127) was 1.47 +/- 2.58 ng/dl, and eight of 120 (6.8%) showed an insufficient IGF-I response (<50% over baseline) to the IGF-I generation test. CONCLUSION: FM patients show a high prevalence of GH axis dysfunction. A significant number of patients show biochemical patterns of GH deficiency as well as some degree of GH resistance and might be potential candidates for substitution treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Giesecke, T., Williams, D. A., Harris, R. E., Cupps, T. R., Tian, X., Tian, T. X., Gracely, R. H., & Clauw, D. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11272 · Cited by 424
Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency
Biller, B. M. K., Samuels, M. H., Zagar, A., Cook, D. M., Arafah, B. M., Bonert, V., Stavrou, S., Kleinberg, D. L., Chipman, J. J., & Hartman, M. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8509 · Cited by 423
Diagnosis of adult GH deficiency
Gasco, V., Corneli, G., Rovere, S., Croce, C., Beccuti, G., Mainolfi, A., Grottoli, S., Aimaretti, G., & Ghigo, E. (2008) · Pituitary · doi:10.1007/s11102-008-0110-x · Cited by 41
Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone
DELITALA, G., TOMASI, P. A., PALERMO, M., ROSS, R. J. M., GROSSMAN, A., & BESSER, G. M. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-2-356 · Cited by 23 · cited 1×
“In relation to other factors that may modify the somatotropic axis activity, antidepressive drugs taken by these patients for long periods of time have not been shown to affect GH axis (13, 22), and opioids seem to stimulate GH secretion rather than diminish it (31).”
BackgroundManaging patients with hypopituitarism after traumatic brain injury
Corneli, G., Ghigo, E., & Aimaretti, G. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3281e7e6e6 · Cited by 13
Cited by
Fibromyalgia: A Critical and Comprehensive Review
Borchers, A. T., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8509-4 · Cited by 275
Review of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188
“Three RCTs of growth hormone (two studies compared with placebo, one as add-on to multicomponent therapy including antidepressants and tramadol) of 157 total patients demonstrated benefits of growth hormone for pain and fatigue after 9 to 18 months [44-46].”
BackgroundLeinders, M., Doppler, K., Klein, T., Deckart, M., Rittner, H., Sommer, C., & Üçeyler, N. (2016) · Pain · doi:10.1097/j.pain.0000000000000668 · Cited by 71
Singh, L., Kaur, A., Bhatti, M. S., & Bhatti, R. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02805-5 · Cited by 55
Metadata
- Authors
- Cuatrecasas, G., Gonzalez, M. J., Alegre, C., Sesmilo, G., Fernandez-Solà, J., Casanueva, F. F., Garcia-Fructuoso, F., Poca-Dias, V., Izquierdo, J. P., & Puig-Domingo, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-09
- Volume
- 95
- Issue
- 9
- Pages
- 4331-4337
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2138658011
- Cited by
- 58
- References
- 6
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Prevalence of Growth Hormone Deficiency in Severe Fibromyalgia Syndromes. https://app.cochat.ai/papers/10.1210/jc.2010-0061
- The paper
- Cuatrecasas, G., Gonzalez, M. J., Alegre, C., Sesmilo, G., Fernandez-Solà, J., Casanueva, F. F., Garcia-Fructuoso, F., Poca-Dias, V., Izquierdo, J. P., & Puig-Domingo, M. (2010). High Prevalence of Growth Hormone Deficiency in Severe Fibromyalgia Syndromes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.